Predictors of recovery of ovarian function during aromatase inhibitor therapy.

ABSTRACT:

Background

Aromatase inhibitors (AIs) may cause a rise in estrogen levels due to ovarian function recovery in women with clinical chemotherapy-induced ovarian failure (CIOF). We carried out a prospective registry trial to identify predictors of ovarian function recovery during AI therapy.

Patients and methods

Women with hormone receptor (HR)-positive breast cancer who remained amenorrheic and had hormonal levels consistent with ovarian failure after adjuvant chemotherapy were enrolled in a multi-institutional clinical trial of anastrozole. Subjects underwent frequent assessment using an ultrasensitive estradiol assay. Multivariable analysis was used to evaluate clinical and biochemical predictors of ovarian function recovery within 48 weeks.

Results

Recovery of ovaria

SUBMITTER: Henry NL 

PROVIDER: S-EPMC3718506 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature